Proline cycle-mediated metabolic reprogramming in gemcitabine resistance of pancreatic cancer.

被引：0
|
作者：
Shen, Yu-Shiuan [1 ]
Huang, Ming-Te [1 ]
Su, Yan-Hao [1 ]
Su, Chih-Ming [1 ]
Chen, Hsin-An [1 ]
机构：
[1] Hosp Tokyo, Dept Surg, Tokyo, Japan
来源：
CANCER SCIENCE | 2021年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PE14-3-2
引用
收藏
页码：760 / 760
页数：1
相关论文
共 50 条
  • [1] Prediction of gemcitabine resistance in patients with pancreatic cancer.
    Nakahira, S.
    Nakamori, S.
    Tsujie, M.
    Okami, J.
    Takemasa, I.
    Takeda, Y.
    Nagano, H.
    Dono, K.
    Sakon, M.
    Monden, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 209S - 209S
  • [2] Metabolic regulation of gemcitabine resistance in pancreatic cancer
    Shukla, S. K.
    CANCER MEDICINE, 2018, 7 : 10 - 10
  • [3] Cell cycle-mediated drug resistance: An emerging concept in cancer therapy
    Shah, MA
    Schwartz, GK
    CLINICAL CANCER RESEARCH, 2001, 7 (08) : 2168 - 2181
  • [4] Metabolic Reprogramming With β-alanine to Overcome Chemotherapy Resistance in Pancreatic Cancer
    Totiger, S.
    Moran, A.
    Suwal, S.
    Pimentel, J.
    O'Donnell, L.
    Walls, J. D.
    Merchant, N.
    Livingstone, A. S.
    Yakoub, D.
    PANCREAS, 2018, 47 (10) : 1429 - 1429
  • [5] Solute carrier (SLC) transporter-mediated metabolic reprogramming during enzalutamide resistance in prostate cancer.
    Verma, Shiv Shankar
    Shankar, Eswar
    Chan, Ricky
    Gupta, Sanjay
    CANCER RESEARCH, 2021, 81 (13)
  • [6] Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts
    Konate, Mariam M.
    Krushkal, Julia
    Li, Ming-Chung
    Chen, Li
    Kotliarov, Yuri
    Palmisano, Alida
    Pauly, Rini
    Xie, Qian
    Williams, P. Mickey
    McShane, Lisa M.
    Zhao, Yingdong
    JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)
  • [7] Metabolic adaptations in pancreatic cancer.
    Wellen, Kathryn E.
    CANCER RESEARCH, 2020, 80 (22)
  • [8] Targeting gemcitabine resistance in pancreatic cancer
    Beutel, Alica Katrin
    Singh, Rima
    Anaraki, Cecily
    Tong, Gregory
    Martinez, Thomas
    Kleger, Alexander
    Jutric, Zeljka
    Halbrook, Christopher James
    CANCER RESEARCH, 2022, 82 (22)
  • [9] Stellate Cells Aid Growth-Permissive Metabolic Reprogramming and Promote Gemcitabine Chemoresistance in Pancreatic Cancer
    Amrutkar, Manoj
    Gladhaug, Ivar P.
    CANCERS, 2021, 13 (04) : 1 - 21
  • [10] Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis
    Schniewind, B
    Christgen, M
    Kurdow, R
    Haye, S
    Kremer, B
    Kalthoff, H
    Ungefroren, H
    INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (02) : 182 - 188
12345